Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Murray N. Silverstein"'
Publikováno v:
Blood. 95:2226-2233
In a 20-year period, 223 patients (median age, 64.8 years) with myelofibrosis with myeloid metaplasia (MMM) had therapeutic splenectomy at our institution. Primary indications for surgery were transfusion-dependent anemia (45.3%), symptomatic splenom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18bd73bbd5c8c0a0481ba334ae66e682
https://doi.org/10.1182/blood.v95.7.2226.007k19_2226_2233
https://doi.org/10.1182/blood.v95.7.2226.007k19_2226_2233
Autor:
Ayalew Tefferi, Murray N. Silverstein
Publikováno v:
Baillière's Clinical Haematology. 11:769-785
The clinical course in both polycythaemia vera (PV) and essential thrombocythaemia (ET) is characterized by significant thrombohaemorrhagic complications and variable risk of disease transformation into myeloid metaplasia with myelofibrosis or acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3011bead7d2e154524c99b1d25168471
https://doi.org/10.1016/s0950-3536(98)80038-3
https://doi.org/10.1016/s0950-3536(98)80038-3
Publikováno v:
British Journal of Haematology. 103:505-511
Twenty-three patients who had myelofibrosis with myeloid metaplasia (MMM) were treated at our institution with 50 courses of splenic irradiation (SI) for symptomatic splenomegaly. The median dose of radiation per course was 277.5 cGy, administered in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a79ec71ced27a7dc686361d42a73ac5e
https://doi.org/10.1046/j.1365-2141.1998.00998.x
https://doi.org/10.1046/j.1365-2141.1998.00998.x
Publikováno v:
Seminars in Thrombosis and Hemostasis. 23:379-383
Anagrelide is an oral imidazoquinazoline agent with an anti-cyclic AMP phosphodiesterase activity and inhibits platelet aggregation in both humans and animals. In addition, it has in humans a species-specific platelet-lowering activity observed at do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2dc3042c68f63a04e34de8ff547dcaa
https://doi.org/10.1055/s-2007-996112
https://doi.org/10.1055/s-2007-996112
Publikováno v:
Blood Reviews. 11:1-7
Among the chronic myeloproliferative disorders, polycythemia vera and essential thrombocythemia are unique because of their association with thrombohemorrhagic manifestations and their relatively indolent clinical course. Patients with essential thro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd6e70a27d000bee8dd658389d47d42
https://doi.org/10.1016/s0268-960x(97)90001-1
https://doi.org/10.1016/s0268-960x(97)90001-1
Publikováno v:
American Journal of Hematology. 46:325-328
Life-threatening portal hypertension (PHN) in patients with chronic myeloproliferative disorders may result from increased portal flow caused by marked splenomegaly or an increased resistance to portal flow from either a large vein thrombosis or an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f78f06aa77fa89a0cb1fa808c040f54e
https://doi.org/10.1002/ajh.2830460412
https://doi.org/10.1002/ajh.2830460412
Publikováno v:
The American journal of medicine. 109(2)
Polycythemia vera and essential thrombocythemia pose specific management issues that distinguish them from other chronic myeloproliferative disorders. They are associated with a better prognosis, as well as a variable risk of thrombohemorrhagic compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd25ef8904ed7ea9f7ae39b39ce3a8ff
https://pubmed.ncbi.nlm.nih.gov/10967156
https://pubmed.ncbi.nlm.nih.gov/10967156
Publikováno v:
British journal of haematology. 99(2)
2-Chlorodeoxyadenosine (2-CdA) is a purine nucleoside analogue with therapeutic activity in low-grade lymphoproliferative disorders. In addition, 2-CdA has a potent myelosuppressive effect, and it has been shown to be toxic to malignant myeloid cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e39125d9a48899ff2504bb4ae89685d8
https://pubmed.ncbi.nlm.nih.gov/9695987
https://pubmed.ncbi.nlm.nih.gov/9695987
Autor:
Robert M. Petitt, Lee A. Forstrom, Murray N. Silverstein, Jerzy S. Tarach, Lawrence A. Solberg, Ayalew Tefferi, Karl J. Oles
Publikováno v:
British journal of haematology. 99(1)
Anagrelide, an inhibitor of platelet aggregation, decreases the number of platelets in normal subjects and in patients with myeloproliferative disorders. We describe studies aimed at discovering the general mechanism(s) by which anagrelide acts. We e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83aedd5965c471e76f133fe683604784
https://pubmed.ncbi.nlm.nih.gov/9359521
https://pubmed.ncbi.nlm.nih.gov/9359521
Autor:
Ayalew Tefferi, Murray N. Silverstein
Publikováno v:
Leukemialymphoma. 22
Agnogenic myeloid metaplasia (AMM) carries the worst prognosis among the chronic myeloproliferative disorders. Substantial bone marrow fibrosis, extramedullary hematopoiesis, anemia and hepatosplenomegaly are the characteristic features of the diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18a59b5ec357ce6ddf4c388beac9b65
https://pubmed.ncbi.nlm.nih.gov/8951788
https://pubmed.ncbi.nlm.nih.gov/8951788